Influence of ghrelin on interdigestive gastrointestinal motility in humans

J. Tack; Depoortere, I.; Bisschops, R.; Delporte, C.; Coulie, B.; Meulemans, A.; Janssens, J.; Peeters, T.
March 2006
Gut;Mar2006, Vol. 55 Issue 3, p327
Academic Journal
Background: Recent studies in animals have shown that ghrelin stimulates upper gastrointestinal motility through the vagus and enteric nervous system. The aim of the present study therefore was to simultaneously investigate the effect of administration of ghrelin on upper gastrointestinal motility and to elucidate its mode of action by measuring plasma levels of gastrointestinal hormones in humans. Materials and methods: Nine healthy volunteers (four males; aged 22–35 years) underwent combined antroduodenal manometry and proximal stomach barostat study on two separate occasions at least one week apart. Twenty minutes after the occurrence of phase III of the migrating motor complex (MMC), saline or ghrelin 40 μg was administered intravenously over 30 minutes in a double blind, randomised, crossover fashion. Ghrelin, motilin, pancreatic polypeptide, glucagon, and somatostatin were measured by radioimmunoassay in blood samples obtained at 15–30 minute intervals. The influence of ghrelin or saline on MMC phases, hormone levels, and intraballoon volume was compared using paired t test, ANOVA, and χ² testing. Results: Spontaneous phase III occurred in all subjects, with a gastric origin in four. Administration of ghrelin induced a premature phase III (12 (3) minutes, p<0.001; gastric origin in nine, p<0.05), compared with saline (95 (13) minutes, gastric origin in two). Intraballoon volumes before infusion were similar (135 (13) v 119 (13) ml; NS) but ghrelin induced a longlasting decrease in intraballoon volume (184 (31) v 126 (21) ml in the first 60 minutes; p<0.05). Administration of ghrelin increased plasma levels of pancreatic polypeptide and ghrelin but motilin, somatostatin, and glucagon levels were not altered. Conclusions: In humans, administration of ghrelin induces a premature gastric phase III of the MMC, which is not mediated through release of motilin. This is accompanied by prolonged increased tone of the proximal stomach.


Related Articles

  • Circulating Gastrointestinal Hormone Abnormalities in Patients With Severe Idiopathic Constipation. Van der Sijp, Joost R. M.; Kamm, Michael A.; Nightingale, Jeremy M. D.; Akkermans, Louis M. A.; Ghatei, Mohammed A.; Bloom, Steven R.; Jansen, Jan B. M.; Lennard-Jones, John E. // American Journal of Gastroenterology;Aug1998, Vol. 93 Issue 8, p1351 

    Objective: This study aimed to determine if there is an abnormality of circulating gastrointestinal hormones in patients with severe idiopathic constipation. Methods: Twelve patients, all female (median age 34 yr) and 12 healthy controls (eight female, median age 32 yr) were studied. A...

  • Regulating Glucagon Secretion: Somatostatin in the Spotlight. Rutter, Guy A. // Diabetes;Feb2009, Vol. 58 Issue 2, p299 

    The author comments on the role of the gastrointestinal hormone somatostatin in regulating glucagon secretion. He notes that a relative excess of glucagon is a sign of all forms of diabetes. He cites studies which stress the contribution of the hormone as a tonic inhibitor of glucagon release...

  • The Effect of Glucagon on the Exocrine Pancreas. Schapiro, Herbert; Ludewig, Robert M. // American Journal of Gastroenterology;Sep1978, Vol. 70 Issue 3, p274 

    Glucagon can depress normal animal and human pancreatic exocrine secretions and modify experimentally-induced pancreatitis in animals. It has yet to be demonstrated that glucagon has any efficacy in the treatment of the diseased pancreas in man. Glucagon might act on the exocrine pancreas by 1....

  • Glucagon, in Concert with Insulin, Supports the Postabsorptive Plasma Glucose Concentration in Humans. Breckenridge, Suzanne M.; Cooperberg, Benjamin A.; Arbelaez, Ana M.; Cryer, Philip E. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA581 

    The article discusses a study which tested the hypothesis that glucagon, together with insulin, supports human postabsorptive plasma glucose concentration. Somatostatin analogue octreotide was infused over four hours in 14 healthy adults involved in the study. It was concluded that the low...

  • Vasoactive Intestinal Peptide--Null Mice Demonstrate Enhanced Sweet Taste Preference, Dysglycemia, and Reduced Taste Bud Leptin Receptor Expression. Martin, Bronwen; Yu-Kyong Shin; White, Caitlin M.; Sunggoan Ji; Wook Kim; Carlson, Olga D.; Napora, Joshua K.; Chadwick, Wayne; Chapter, Megan; Waschek, James A.; Mattson, Mark P.; Maudsley, Stuart; Egan, Josephine M. // Diabetes;May2010, Vol. 59 Issue 5, p1143 

    OBJECTIVE--It is becoming apparent that there is a strong link between taste perception and energy homeostasis. Recent evidence implicates gut-related hormones in taste perception, including glucagon-like peptide 1 and vasoactive intestinal peptide (VIP). We used VIP knockout mice to investigate...

  • Insulin's direct effects on the liver dominate the control of hepatic glucose production. Edgerton, Dale S.; Lautz, Margaret; Scott, Melanie; Everett, Carrie A.; Stettler, Kathryn M.; Neal, Doss W.; Chu, Chang A.; Cherrington, Alan D. // Journal of Clinical Investigation;Feb2006, Vol. 116 Issue 2, p521 

    Insulin inhibits glucose production through both direct and indirect effects on the liver; however, considerable controversy exists regarding the relative importance of these effects. The first aim of this study was to determine which of these processes dominates the acute control of hepatic...

  • Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro- duodenal motility in humans. Schirra, J.; Nicolaus, M.; Roggel, R.; Katschinski, M.; Storr, M.; Woerle, H. J.; Göke, B. // Gut;Feb2006, Vol. 55 Issue 2, p243 

    Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1 ) lowers glycaemia by stimulation of insulin, inhibition of glucogon, and deice, of gastric emptying. Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic secretion and antro-pyloroduodenal...

  • GLP-1: target for a new class of antidiabetic agents? Edwards, Mark B. // Journal of the Royal Society of Medicine;Jun2004, Vol. 97 Issue 6, p270 

    The article provides information on glucagon-like peptide-1 (GLP-1) hormone. GLP-1 and glucose-dependent insulinotropic peptide are responsible for the differences between 2 values known as the incretin effect. This GLP-1 decreases the glucose levels of type 2 diabetic patient and stimulates...

  • Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice. Min He; Haoran Su; Weiwei Gao; Johansson, Stina M.; Qing Liu; Xiaoyan Wu; Jiayu Liao; Young, Andrew A.; Tamas Bartfai; Ming-Wei Wang // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Background: Glucagon-like peptide-1 (GLP-1) is recognized as an important regulator of glucose homeostasis. Efforts to utilize GLP-1 mimetics in the treatment of diabetes have yielded clinical benefits. A major hurdle for an effective oral therapy has been the difficulty of finding a...


Read the Article


Sign out of this library

Other Topics